These Are Sectors Where Seed Rounds Of $5M To $10M Are Clustering This Year
Crunchbase News analyzed roughly 800 global seed financings in the $5M–$10M range this year and identified four standout sectors: proptech, cancer therapeutics, space tech, and robotics.
Intelligence analysis by Llama
Crunchbase News crunched ~800 mid-sized seed rounds worldwide and found clustering in proptech, cancer therapeutics, space tech, and robotics — a sign that investors are still willing to back modestly funded teams on ambitious missions.
Imagine you have a small bag of marbles and you want to bet on which kid in class might build something cool one day. Crunchbase looked at hundreds of small bets ($5M–$10M) and noticed lots of them going to four kinds of startups: ones that make building houses smarter, ones that try to cure cancer, ones that build things for space, and ones that build robots.
Analysis
Real Estate's Quiet Reinvention
Proptech's place on this list is notable because the underlying market dwarfs venture activity. Real estate accounts for roughly two-thirds of global net worth, according to a McKinsey & Company estimate cited in the article, yet last year's proptech startup investment totaled just over $10 billion — far below prior peaks. Seed investors appear to be reading that gap as opportunity rather than saturation. The companies landing $5M–$10M rounds are tackling concrete, unglamorous problems: AI-powered home management (Hint), software for real estate decarbonization (Optiml), and AI-enabled construction supply chains (Krane). These aren't moonshots — they're targeted bets on efficiency in a market long overdue for software-driven productivity gains.
Biology, Orbit, and Bots
The remaining three sectors share a common thread: each tackles a problem domain that is technically hard, capital-intensive at scale, but accessible in early form with a small team and a modest check. Cancer therapeutics is perhaps the most obvious. With 39% of Americans projected to receive a cancer diagnosis in their lifetime, the addressable patient population is vast, and seed investors are willing to back early-stage therapeutic and diagnostic platforms. Three California startups — Rybodyn, Vivere Oncotherapies, and Valius Sciences — each raised $10 million, the top of the sample range. Space tech, meanwhile, was buoyed this year by the SpaceX IPO, but the seed activity sits well below that headline. Reusable satellites (Lux Aeterna), in-space propulsion (InSpacePropulsion Technologies), and ML-native satellite operations (Constellation Space) suggest the post-SpaceX generation is already taking shape. Robotics rounded out the list and was the most geographically dispersed sector, with companies spread across Asia, North America, Europe, and Australia, including Somnia Lab's "intimacy robots," Bubble Robotics' autonomous underwater vehicles, and Eternal.ag's greenhouse harvesters.
Small Checks, Grand Missions
The article's central editorial point is that mid-sized seed rounds reveal something megarounds cannot: which sectors investors trust to a small, unproven team. In a market where the biggest deals tend to feature serial entrepreneurs or established traction, the $5M–$10M bracket is closer to the classic seed bet — a risky wager on founders, technology, and business model all at once. The fact that this year's clustering spans real estate, oncology, orbit, and robotics suggests investors still believe modest capital can launch outsized missions. That is, on its own, a useful counterweight to the narrative that venture has become a winner-take-all game dominated by AI infrastructure plays and late-stage consolidations. For founders in these four verticals, the signal is constructive: there is active, thesis-driven seed capital available, and the entry bar is a credible technical plan rather than a marquee lead investor.
Key points
- Crunchbase News analyzed ~800 global seed financings in the $5M–$10M range closed this year.
- Proptech stood out despite total sector investment remaining below prior peaks; standouts include Hint, Optiml, and Krane.
- Cancer therapeutics drew multiple $10M seed rounds, with Rybodyn, Vivere Oncotherapies, and Valius Sciences among the top.
- Space tech seed activity sat in the shadow of the SpaceX IPO; Lux Aeterna led with the largest round in the sample.
- Robotics was the most geographically diverse sector, with notable seed-backed companies in Asia, North America, Europe, and Australia.
If these seed-stage bets mature into venture-scale outcomes, the four sectors could each produce the next generation of category-defining companies, with seed investors reaping early-entry returns. The geographic spread in robotics alone suggests a globally distributed innovation base that could compound over the next decade.
Seed-stage clustering can also signal overheating. Concentrated investor attention in proptech, oncology, and space tech could drive up early-stage valuations, leaving later rounds underfunded if clinical trials, satellite launches, or commercial pilots underperform. The article's own data point — proptech investment still well below prior peaks — is a reminder that sector enthusiasm does not always translate into returns.
